Cost Insights: Breaking Down Catalent, Inc. and Alkermes plc's Expenses

Catalent vs. Alkermes: A Decade of Cost Dynamics

__timestampAlkermes plcCatalent, Inc.
Wednesday, January 1, 20144478750001229100000
Thursday, January 1, 20154833930001215500000
Friday, January 1, 20165192700001260500000
Sunday, January 1, 20175676370001420800000
Monday, January 1, 20186018260001710800000
Tuesday, January 1, 20196932180001712900000
Wednesday, January 1, 20205729040002111000000
Friday, January 1, 20216039130002646000000
Saturday, January 1, 20222181080003188000000
Sunday, January 1, 20232530370003216000000
Monday, January 1, 20243428000000
Loading chart...

In pursuit of knowledge

Cost Insights: Catalent, Inc. vs. Alkermes plc

In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. From 2014 to 2023, Catalent, Inc. and Alkermes plc have shown distinct trends in their cost of revenue. Catalent's expenses have surged by approximately 178%, peaking in 2023, while Alkermes experienced a 44% drop in 2022, followed by a slight recovery in 2023. This divergence highlights Catalent's aggressive growth strategy, possibly driven by increased production and expansion efforts. Meanwhile, Alkermes' fluctuating costs may reflect strategic shifts or market challenges. Notably, Catalent's costs consistently outpaced Alkermes, underscoring its larger operational scale. As we look to 2024, Catalent's data remains robust, while Alkermes' figures are yet to be revealed, leaving room for speculation on future strategies. This analysis offers a window into the financial dynamics shaping these industry players, providing valuable insights for investors and stakeholders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025